Receptor tyrosine kinases: From biology to pathology

Journal of Receptors and Signal Transduction

Volumn 31, Issue 6, 2011, Pages 387-394

  Choura, Mouna ^a   Rebaï, Ahmed ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Disease; human; ligand; mutation; RTK

Indexed keywords

EPHRIN RECEPTOR; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INSULIN RECEPTOR; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

CELL DIFFERENTIATION; CELL GROWTH; GENE REARRANGEMENT; GENE SILENCING; HUMAN; NUCLEOTIDE SEQUENCE; REVIEW; SOMATIC MUTATION;

GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

METAZOA;

EID: 80955158149     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2011.625425     Document Type: Review

References (48)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
2. Patthy L. Modular exchange principles in proteins. Curr Opin Struct Biol 1991, 1, 351-361. (Pubitemid 121002540)
3. Patthy L. Introns and exons. Curr Opin Struct Biol 1994, 4, 383-392. (Pubitemid 24195855)
4. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993, 62, 453-481. (Pubitemid 23237878)
5. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80, 213-223.
6. Drescher U. Eph family functions from an evolutionary perspective. Curr Opin Genet Dev 2002, 12, 397-402. (Pubitemid 34722917)
7. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994, 368, 643-648. (Pubitemid 24153389)
8. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117-1134.
9. Bae JH, Schlessinger J. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol Cells 2010, 29, 443-448.
10. Brognard J, Hunter T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev 2011, 21, 4-11.
11. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411, 355-365. (Pubitemid 32467045)
12. Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006, 45, 6241-6251. (Pubitemid 43787791)
13. Sigalov AB, editor. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease. Springer-Verlag, New York, 2008.
14. Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromes when good receptors turn bad. Trends Genet 2000, 16, 265-271. (Pubitemid 30332143)
15. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19, 3159-3167. (Pubitemid 30428195)
16. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010, 5, 1734-1740.
17. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23, 2556-2568.
18. Yun YR, Won JE, Jeon E, Lee S, Kang W, Jo H, Jang JH, Shin US, Kim HW. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010, 2010, 218142.
19. Wilikie AO. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005, 16, 187-203.
20. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006, 24, 3747-3755. (Pubitemid 46622313)
21. Raile K, Klammt J, Schneider A, Keller A, Laue S, Smith R, Pfäffle R, Kratzsch J, Keller E, Kiess W. Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor i receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1R. J Clin Endocrinol Metab 2006, 91, 2264-2271. (Pubitemid 43855016)
22. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934. (Pubitemid 35425239)
23. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10, 165-180.
24. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26, 5352-5359.
25. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990, 87, 1377-1380.
26. Springall F, O'Mara S, Shounan Y, Todd A, Ford D, Iland H. c-fms point mutations in acute myeloid leukemia: fact or fiction? Leukemia 1993, 7, 978-985. (Pubitemid 23230976)
27. Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 2009, 10, 1839-1851.
28. Mäkinen T, Norrmén C, Petrova TV. Molecular mechanisms of lymphatic vascular development. Cell Mol Life Sci 2007, 64, 1915-1929. (Pubitemid 47094431)
29. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000, 25, 153-159. (Pubitemid 30394984)
30. Lehmann K, Seemann P, Silan F, Goecke TO, Irgang S, Kjaer KW, Kjaergaard S, Mahoney MJ, Morlot S, Reissner C, Kerr B, Wilkie AO, Mundlos S. A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN. Am J Hum Genet 2007, 81, 388-396. (Pubitemid 47236086)
31. Katoh M, Katoh M. Comparative integromics on non-canonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells. Int J Mol Med 2007, 20, 405-409.
32. Kaplan DR, Stephens RM. Neurotrophin signal transduction by the Trk receptor. J Neurobiol 1994, 25, 1404-1417. (Pubitemid 24325065)
33. Sarasola Rodriguez JA, Garrote E, Aristegui J, Garcia-Barcina MJE. A short in-frame deletion in NRTK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensivity to pain with anhidrosis. BMC Med Genet 2011, 12, 86.
34. Guo H, Barrett TM, Zhong Z, Fernández JA, Griffin JH, Freeman RS, Zlokovic BV. Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartatetreated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener 2011, 6, 13.
35. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, Kay NE. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011, 117, 1928-1937.
36. Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 2011, 71, 1792-1804.
37. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994, 5, 647-657. (Pubitemid 24252329)
38. Chan MC, Mather JP, McCray G, Lee WM. Identification and regulation of receptor tyrosine kinases Rse and Mer and their ligand Gas6 in testicular somatic cells. J Androl 2000, 21, 291-302. (Pubitemid 30123711)
39. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, Oyesiku NM. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2001, 86, 3097-3107. (Pubitemid 32673472)
40. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102, 2951-2959. (Pubitemid 37248870)
41. Funakoshi H, Yonemasu T, Nakano T, Matumoto K, Nakamura T. Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons. J Neurosci Res 2002, 68, 150-160. (Pubitemid 34275008)
42. Saharinen P, Bry M, Alitalo K. How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 2010, 17, 198-205.
43. Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996, 87, 1181-1190. (Pubitemid 27010102)
44. Sagara Y, Miyata Y, Nomata K, Abe K, Eguchi J, Hayashi T, Sakai H, Kanda S, Kanetake H. TFE3-renal carcinoma in an adult patient: a case with strong expression of phosphorylated hepatocyte growth factor (HGFR)/Met. Pathol Res Pract 2009, 205, 57-61.
45. Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 2011, 71, 1945-1955.
46. Qi XP, Ma JM, Du ZF, Ying RB, Fei J, Jin HY, Han JS, Wang JQ, Chen XL, Chen CY, Liu WT, Lu JJ, Zhang JG, Zhang XN. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. PLoS ONE 2011, 6, e20353.
47. Martínez I, Mantilla A, Medrano ME, Hernández R, Hernández DM, Lazos M, Santiago H, González B, Hidalgo A, Salcedo M. High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas. Endocr Pathol 2001, 12, 113-123. (Pubitemid 32826469)
48. Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, BauchéS, Prioleau C, Herbst R, Goillot E, Ioos C, Azulay JP, Attarian S, Leroy JP, Fournier E, Legay C, Schaeffer L, Koenig J, Fardeau M, Eymard B, Pouget J, Hantaï D. Towards the molecular elucidation of congenital myasthenic syndromes: identification of mutations in MuSK. Acta Myol 2005, 24, 55-59. (Pubitemid 43287336)